

FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO..  
PU3517USW

SERIAL NO.  
10/070,084

APPLICANT  
Andrews et al.

FILING DATE  
03/01/02

GROUP

O I P E  
JAN 22 2003

PATENT & TRADEMARK OFFICE  
U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
AC	5,945,450	31 Aug. 1999	Takenouchi, et. al.			
AD	5,719,143	17 Feb. 1998	Badore, et al.			

Continue on page

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes	Translation No
	BC	EP 0667344A1	13 Feb. 1995	EPO			English abstract	
	BD	WO 93/15043	8 May 1993	PCT			English abstract	
	BE	JP 59 181246	1984-10-15	JP			English abstract	

Continue on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

CE	De Clercq, "Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection," Il Farmco, 1999, Vol. 54, pgs 26-45.
CF	Balzarini, "Suppression of Resistance to Drugs Targeted to Human Immunodeficiency Virus Reverse Transcriptase by Combination Therapy," Biochemical-Pharmacology, 1999, Vol. 58, p. 1-
CG	Inaba, et. al., "Benzodiazepines. V. A Novel Synthesis of a 7-Nitro-1,4-benzodiazepine Derivative," Chem. Pharm. Bull., 1971, Vol. 19, p. 722.

Continue on page

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP-§ 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#9  
9/29/03  
83  
RECEIVED  
JAN 24 2003  
TECH CENTER 1600/2900

In the application of: Andrews et al.

Serial No.: 10/070,084 ✓

Group Art Unit: 1614

Filed: March 1, 2002

Examiner:

For: Benzophenones as Inhibitors of Reverse Transcriptase ✓

Commissioner for Patents  
Washington, D.C. 20231

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

Copies of the references are enclosed: AC, BC-BE, CE-CG  
 Copies of the references were submitted in parent application Serial No. \_\_\_\_\_ (37 CFR 1.98(d))  
 A copy of the International Search Report, which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A.  The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

B.  The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

(1) a final action under § 1.113 or  
(2) a notice of allowance under § 1.311,

whichever occurs first.

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

C.  The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):


Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).

The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

Please charge required fees to Deposit Account No.07-1392.  
 A duplicate copy of this paper is attached.

Respectfully Submitted,



Karen L. Prus

Registration No. 39,337


Date: January 16, 2008  
GlaxoSmithKline  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Telephone: (919) 483-2192  
Facsimile: (919) 483-7988

## CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Andrews et al.

Docket No.

PU3517USW

Serial No.  
10/070,084Filing Date  
March 1, 2002

JAN 22 2003

Examiner

Group Art Unit  
1614

Invention: Benzophenones as Inhibitors of Reverse Transcriptase

I hereby certify that this Supplemental Information Disclosure with accompanying papers  
 (Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The  
 Commissioner of Patents and Trademarks, Washington, D.C. 20231-0001 on Jan. 16, 2003  
 (Date)

Valerie L. Phillips

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)